Search results
Showing results for
Companies start in all kinds of different ways, and for Bioarchitech it was brainstorming that generated the idea behind the enterprise. It is now planning a Series A fundraising to bring its lead candidate to the clinic. Bioarchitech is focused on cancer, developing oncolytic viruses encoding protein immunotherapies for the destruction of tumours, ideally with just one or two doses.
Accessibility Statement
The University of Oxford is committed to providing an accessible web presence that gives members of the public and members of the University community full access to University information, courses and activities offered publicly through the web. Our Equality Policy outlines our commitment to a culture which ‘maintains a working, learning and social environment in which the rights and dignity of all its staff and students are respected’.
"We loved being in the BioEscalator, and part of the community, and the support and flexibility from the BioEscalator team was invaluable."
Hollie Coe, Base Genomics (now Exact Sciences Innovation)
"The high-quality facilities, resources and support to grow a company were invaluable."
Tim Funnell, MiroBio (now Gilead)
